pharmaphorum

JUNE 8, 2021

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. In 2001, he joined as a principal scientist in the oncology team in the drug discovery division and associate director at Johnson & Johnson. Chemotherapy still accounted for 72.6%

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

PharmaShots

JANUARY 31, 2023

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Founded Year: 2008 No. Funding Value: $7.7M Founded Year: 2021 No. of Shares: 1.3M In Sep’22 stakeholders exercised 0.7M tradable warrants and 0.3M

Vaccines 40

Vaccines Immunization Immunity Diabetes 40

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Vaccines 52

Vaccines Communication Immunity Immunization 52

Pharmaceutical Technology

AUGUST 26, 2008

In December 2006 it acquired MacroMed Inc, a privately owned speciality drug development and manufacturing company based in the US, for its lead product OncoGel™ for the treatment of oesophageal and brain cancers. The DEEP study results, along with data from further analyses, are under review by a potential licensing partner.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 40